Scholar Rock Wins FDA Approval for ISEMBYLD, First Muscle-Targeted Treatment for Spinal Muscular Atrophy Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company focused on developing therapies for rare, severe and debilitating neuromuscular diseases through its expertise in myostatin biology, announced…
Bausch + Lomb Receives European CE Mark for Next-Generation SeeLyra Femtosecond Laser Bausch + Lomb Corporation (NYSE/TSX: BLCO), a global eye health company focused on helping people see better and live better, has announced that its next-generation SeeLyra femtosecond laser…
Nutromics Receives FDA Breakthrough Device Designation for Wearable Vancomycin Monitoring Patch Nutromics, a medical technology company developing a wearable lab-on-a-patch™ platform for continuous molecular monitoring, announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation (BDD)…
Mirum Pharmaceuticals Appoints Rob Myers, M.D. as Chief Medical Officer to Lead Global Medical and Clinical Development Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a rare disease-focused pharmaceutical company developing medicines for patients with serious and often underserved conditions, has announced the…
Prilenia Therapeutics Appoints Neurology Expert Rick Munschauer as Chief Medical Officer Prilenia Therapeutics B.V., a biopharmaceutical company focused on developing potential treatments for neurodegenerative diseases, has announced the appointment of Frederick (Rick) E. Munschauer III, MD, MSc, FAAN, as its…
Teleflex Appoints Sean M. Salmon to Board of Directors to Support Strategic Growth Teleflex Incorporated, a global provider of medical technologies, has announced the appointment of Sean M. Salmon to its Board of Directors, effective September 8, 2026. The appointment…
Ionis Pharmaceuticals Receives FDA Approval for ZANVASTRO, First Disease-Modifying Treatment for Alexander Disease Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) has announced that the U.S. Food and Drug Administration (FDA) has approved ZANVASTRO™ (zilganersen) for the treatment of pediatric and adult patients…
BNB Plus Appoints Three New Directors to Support Strategic Transformation and Digital Infrastructure Growth BNB Plus Corp., referred to as “BNB Plus” or the “Company,” has announced the appointment of three new members to its Board of Directors as part…
Tobias Janowitz Appointed to Lead Cancer Research at Feinstein Institutes and Northwell Health The Feinstein Institutes for Medical Research has announced the appointment of Tobias Janowitz, MD, PhD, as director of its Institute of Cancer Research, marking a significant step…
BeOne Medicines Receives FDA Approval for TEVIMBRA Combination in First-Line HER2-Positive Gastroesophageal Cancer BeOne Medicines Ltd., a global oncology-focused biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for TEVIMBRA®…
Daiichi Sankyo Appoints Ken Keller as Chief Commercialization Officer to Accelerate Global Oncology and Specialty Medicine Growth Daiichi Sankyo has announced the appointment of Ken Keller to the newly created position of Chief Commercialization Officer, marking a significant step in…
ORZEYFUL (oveporexton) Gains Japanese Approval as the First and Only Medicine Addressing the Underlying Cause of Narcolepsy Type 1 Takeda has announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved ORZEYFUL (oveporexton) for the treatment of adults…